Table 2b.
Marked beta-agonist overuse without medical review
| Outcome | SMART group (N = 151) | Standard group (N = 152) | Relative risk or rate SMART vs Standard (95% CI) | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | Mean (SD) | Median (IQR) | Range | N (%) | Mean (SD) | Median (IQR) | Range | Risk | Rate | ||
| At least one episode of marked overuse | 54 (36) | 56 (37) | 0·97 (0·72–1·31) | – | 0·85 | ||||||
| Number of days of marked overuse | 2·6 (10·2) | 0 (0–1) | 0–109 | 4·8 (14·9) | 0 (0–2) | 0 to 144 | – | 0·56 (0·35–0·88) | 0·013 | ||
| Number of days of marked overuse in participants with at least one marked overuse episode | 7·4 (16·0) | 2 (1–7) | 1–109 | 13·1 (22·3) | 4·5 (2 to 15) | 1–144 | – | – | – | ||
| Number of days of marked overuse without medical review within 48 h in participants with at least one marked overuse episode | 6·7 (15·7) | 2 (1–6) | 1–109 | 11·7 (19·0) | 4 (2–14) | 0–118 | – | 0·62 (0·37–1·06) | 0·079 | ||
| Proportion of marked overuse days without medical review within 48 h compared to total marked overuse days in participants with at least one high use episode | 0·94 (0·17) | 1 (0·74–1) | 0·15–1 | 0·92 (0·19) | 1 (0·96–1) | 0–1 | – | – | – | ||